Revenue Estimates Analysis AbbVie Inc. (ABBV)

Monday, 26 Mar, 2018

This repurchase authorization allows the company to buy shares of its stock through open market purchases. Over the last three months, insiders sold 211,197 shares of company stock valued at $24,585,575. After a recent check, AbbVie Inc., (NYSE: ABBV)'s last month price volatility comes out to be 3.05% which for the week stands at 4.04%.

Berkshire Partners Llc holds 18.7% of its portfolio in Advanced Drainage Systems, Inc. for 5.26 million shares.

AbbVie (NYSE ABBV) opened at $97.46 on Monday. It has outperformed by 20.61% the S&P500.

Edgewood Management Llc decreased Abbvie Inc (ABBV) stake by 4.85% reported in 2017Q3 SEC filing. The company has a debt-to-equity ratio of 6.07, a quick ratio of 1.18 and a current ratio of 1.28. The hedge fund run by John Burbank held 180,452 shares of the business services company at the end of 2017Q3, valued at $31.17 million, up from 177,285 at the end of the previous reported quarter. The stock decreased 1.90% or $1.27 during the last trading session, reaching $65.7. About 4.16M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since March 26, 2017 and is uptrending. GONZALEZ RICHARD A sold $976,084 worth of AbbVie Inc. (NYSE:ABBV) was sold by SEVERINO MICHAEL. They expect $1.78 EPS, up 39.06% or $0.50 from last year's $1.28 per share. ABBV's profit will be $2.82 billion for 13.13 P/E if the $1.78 EPS becomes a reality.

EPS growth estimate for this year is set at 52.60%.The earnings per share (EPS) formula is stated as earnings available to common shareholders divided by number of common stock shares outstanding. It also increased its holding in Guggenheim Bulletshrs 2020 Hy Corpbd Etf (BSJK) by 60,612 shares in the quarter, for a total of 636,202 shares, and has risen its stake in Schwab Emerging Markets Equity Etf (SCHE).

Investors sentiment decreased to 0.8 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It dropped, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. Checchi Cap Advisers Lc reported 0.14% in AbbVie Inc. At the moment, the 14-days ATR for AbbVie Inc. (NYSE:ABBV) by 2.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. Cypress Asset Incorporated Tx has 20,583 shares for 0.39% of their portfolio. Autus Asset Mngmt Limited Liability Co owns 15,175 shares or 0.26% of their U.S. portfolio. Loring Wolcott & Coolidge Fiduciary Llp Ma reported 0.19% in AbbVie Inc.

In other news, insider Laura J. Schumacher sold 25,000 shares of the business's stock in a transaction on Thursday, March 1st. $1.66M worth of AbbVie Inc. (NYSE:ABBV) for 148,228 shares. Swarthmore holds 0.07% in AbbVie Inc. Iguana Healthcare Mgmt Ltd Limited Liability Company reported 3.22% stake. Welch Grp Inc invested in 254,231 shares or 3.78% of the stock. (NYSE:ABBV). Cubist Systematic Strategies Ltd Llc has invested 0.08% of its portfolio in AbbVie Inc. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Therefore 45% are positive. According to these analysts, the Low Revenue Estimate for AbbVie 7.38 Billion and the High Revenue Estimate is 7.69 Billion. The stock has "Outperform" rating by Cowen & Co on Wednesday, October 11. The firm has "Hold" rating by Deutsche Bank given on Monday, July 17. The firm has " rating given on Monday, September 28 by Citigroup. The firm earned "Hold" rating on Monday, January 29 by Credit Suisse. SELL rating has been given by 0 analyst (s) and 0 analyst (s) given BUY rating to the stock. The rating was maintained by Jefferies with "Buy" on Friday, January 26. Morgan Stanley upgraded the shares of ABBV in report on Monday, November 2 to "Overweight" rating.

Companies that can increase earnings at a high compound rate over time are attractive to investors.

Since September 28, 2017, it had 0 insider buys, and 13 insider sales for $49.94 million activity. Hyman Charles D has invested 0.26% in AbbVie Inc. Leerink Swann also issued estimates for AbbVie's Q4 2018 earnings at $2.02 EPS, FY2018 earnings at $7.53 EPS, FY2019 earnings at $9.08 EPS, FY2020 earnings at $9.76 EPS, FY2021 earnings at $10.49 EPS and FY2022 earnings at $11.22 EPS. ALBAN CARLOS also sold $9.57 million worth of AbbVie Inc. RICHMOND TIMOTHY J. had sold 18,129 shares worth $2.15M. (WMS) has declined 0.13% since March 26, 2017 and is downtrending. Aperio Gp Lc invested in 865,283 shares. INTC's free cash flow ("FCF") per share for the trailing twelve months was +0.40. Insiders own 0.07% of the company's stock. (NASDAQ:SUPN) for 8,671 shares. United Fire accumulated 225,000 shares or 6.73% of the stock. Bahl Gaynor holds 2.12M shares or 2.06% of its portfolio. (NYSE:ABBV). Fort Washington Inv Oh invested in 0.18% or 132,979 shares. Hbk Sorce Advisory Limited Com reported 13,227 shares. Bnp Paribas Arbitrage has 26,072 shares. The rating was initiated by Leerink Swann on Tuesday, October 18 with "Mkt Perform". Therefore 95% are positive. Amdocs had 22 analyst reports since July 30, 2015 according to SRatingsIntel. On Tuesday, September 5 the stock rating was maintained by Jefferies with "Buy". SunTrust maintained Alibaba Group Holding Limited (NYSE:BABA) rating on Friday, August 12. The rating was maintained by Jefferies with "Buy" on Friday, March 23. The rating was downgraded by PiperJaffray to "Neutral" on Monday, July 17. $2.95 million worth of AbbVie Inc. The stock has "Buy" rating by Goldman Sachs on Friday, March 10. The firm has "Buy" rating by Jefferies given on Thursday, May 25. The stock of Supernus Pharmaceuticals, Inc. The firm now has a buy rating on the stock. (NASDAQ:SUPN) has "Buy" rating given on Tuesday, January 2 by Stifel Nicolaus.